Accenture heads into its October 1 earnings report with the data telling a markedly different story than it did ahead of the September 24 print — shorts have unwound further, the borrow market stays wide open, and the Street's dominant move this past week has been upward target revisions.
The short-position unwind that was already underway before last week's report has accelerated since. Shares short dropped another 4.9% in a single session on September 24 and are down nearly 7% on the week, bringing the position to 24.1 million shares — 3.9% of the free float. That's a 19% decline from the early-September peak above 25.9 million and roughly 23% below the early-August high near 31 million. Availability remains overwhelmingly loose at 1,739% of current short interest, meaning the lending pool is not a constraint on either new shorts or exits. Borrowing costs have edged up 38% on the week to 0.65%, but at that absolute level the borrow is still trivially cheap. The ORTEX short score has drifted down to 38.4 — a reading that places ACN in the lower half of the universe for short-squeeze risk — consistent with a position that is gradually coming off rather than building.
Options positioning has turned slightly more defensive into this print than was evident before last week's event, though still far from alarming. The put/call ratio has moved to 0.99, just above its 20-day average of 0.97 and running at roughly 1.3 standard deviations above that mean. That is elevated but well short of the defensive extremes seen earlier in September. The 52-week high on the PCR is 1.01 — the current reading is barely below that ceiling — so there is some hedging demand, but the move is incremental rather than panicked. The stock itself is down 5.8% over the past month to $176.11, and peers have moved similarly: fell 4.2% on the week and dropped 5.1%, suggesting the weakness in Accenture reflects sector-level pressure rather than idiosyncratic selling.
The analyst debate has shifted more constructive in the days since the September 24 print. JP Morgan raised its target to $200 from $179 while holding Overweight, and BMO Capital lifted to $200 from $150 at Market Perform — both moves filed within the past two days. Those follow earlier September raises from Morgan Stanley, Deutsche Bank, and Wolfe Research. The bullish argument centres on Accenture's AI positioning and end-to-end service capability as a durable competitive moat through the current demand trough. Bears counter with ongoing pricing pressure, slower consulting bookings, and a difficult path to margin expansion — Guggenheim's downgrade to Neutral earlier this month reflects exactly that concern. The consensus mean target of $192 implies roughly 9% upside from the current price, a gap that has narrowed as the stock recovered partially from its year-to-date decline of around 34%. Valuation has re-rated materially: the trailing P/E has compressed by more than a point over the past month to 11.5x, and EV/EBITDA has contracted by 0.7x over the same period — the stock is cheaper on multiples than it was, which anchors the bull case but also reflects genuine fundamental uncertainty.
The October 1 print will test whether Accenture's bookings trajectory is stabilising — and whether the AI-driven demand narrative is beginning to show up in actual revenue conversion or remains a forward-looking promise.
See the live data behind this article on ORTEX.
Open ACN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
